BRCA1 and BRCA2 mutation analysis
Material: | 1 – 2 ml EDTA-blood and consent declaration, further material such as tumor biopsy material on request |
Methods: | Amplifikationsverfahren → PCR und Sequenzierung |
Indication | Diagnostic or predictive test in case of positive familial anamnesis for breast- and/or ovarial cancer. |
Please note | Approximately 10 % of all breast cancers and 15 % of all ovarial cancers are by autosomal dominant inheritance and based on mutations in the BRCA1 and BRCA2 genes. Mutation carriers have an increased risk by up to 80 % of developing breast cancer and a 20 – 40 % risk for ovarial cancer. Caution: In case of predictive testing, human genetic counselling is required. |
External services | ja MVZ Dr. Eberhard & Partner Dortmund |
More Results for the letter B
- Babesiosis (BABE)
- Babesia
- Bacillus anthracis (BACIL A)
- Anthrax
- Balantidium coli (BALAN CO)
- Intestinal parasites
- Barbiturates (BARB)
- Bartonella henselae (KKKH)
- previously Rochalimaea henselae
- Bartonella quintana (KKKQ)
- previously Rochalimaea quintana
- BCR-ABL fusion gene (PHIL)
- Philadelphia translocation/ t9 / 22
- Bence-Jones proteins in the urine (BENCE)
- Benperidol (BENP)
- Benzene/Benzol (BENZOL)
- Benzodiazepines, Benzodiazepine differentiation (BENZ)
- Beryllium (BERYL)
- Be
- Bile acids in the serum (GALL)
- Bile acids in the stool (GALLS)
- Bile duct epithelium autoantibodies (GALEP)
- Bilharziasis (SCHIS)
- Schistosomiasis
- Biliary canaliculi, autoantibodies to (BILI02)
- Biliary epithelial cells of the small bile ducts, autoantibodies to (BILI03)
- Biliary pigments (BILI01)
- Bilirubin in the serum, direct (BILD)
- conjugated
- Bilirubin in the serum, indirect (BIIN)
- non-conjugated bilirubin
- Bilirubin in the serum, total (BILI)
- Biotin (VITH)
- Vitamin H
- Biotinidase (BIOTIN)
- Bivaracetam (BIVA)
- Blastocystis hominis (BLASTO)
- intestinal parasites
- Blastomycosis (BLAS)
- Blastomyces dermatitidis
- Bleeding time (Bleet)
- Blood count (KBB)
- Blood culture (BLUTKUL)